scispace - formally typeset
G

Gerald A. Faich

Researcher at Food and Drug Administration

Publications -  10
Citations -  3792

Gerald A. Faich is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Celecoxib & Diclofenac. The author has an hindex of 7, co-authored 10 publications receiving 3701 citations.

Papers
More filters
Journal ArticleDOI

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

TL;DR: The hypothesis of a class adverse effect of cyclooxygenase 2 specific inhibitors on the CV system is not supported and the incidences of adverse CV events such as hypertension, edema, and congestive heart failure were similar to, or significantly lower than, NSAID comparators regardless of the use of ASA.
Journal ArticleDOI

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

TL;DR: In this paper, the authors analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database.
Journal ArticleDOI

Effects of exposure to benzodiazepine during fetal life.

TL;DR: Examination of benzodiazepine use during pregnancy in 104,000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83 concluded that the high rate of teratogenicity after heavy maternal benzodiazine use occurs with multiple alcohol and substance exposure and thus may not be due to benzdiazepine exposure.
Journal ArticleDOI

Streptococcal Pharyngitis and Acute Rheumatic Fever in Rhode Island

Scott D. Holmberg, +1 more
- 04 Nov 1983 - 
TL;DR: Current throat culture practices probably have little influence on treatment of streptococcal pharyngitis and control of rheumatic fever in the state.